Skip to main content

Year: 2020

Neurodegenerative Diseases Drugs Market Expands at 7.2% CAGR and Hit USD 62,786.2 Million by 2026; Biogen and F. Hoffmann-La Roche Ltd Cover More than Half of the Share: Fortune Business Insights

Pune, Nov. 12, 2020 (GLOBE NEWSWIRE) — The global neurodegenerative diseases drugs market size is expected to derive growth from the rising prevalence of neurodegenerative diseases especially among the aging population. In 2018, the global market was valued at US$35,497.3 Mn and is projected to be worth US$ 62,786.2 Mn by 2026. At this pace, the global market is estimated to exhibit a healthy CAGR of 7.2% during the forecast duration.  North America market was valued at US$ 18,174.6 Mn and is anticipated to maintain its dominance throughout the forecast years. Neurodegenerative diseases have become more prevalent in the U.S. owing to an increasingly aging population.Key Industry Developments:In March 2019, Novartis AG announced the FDA approval for Mayzent, an immunomodulator for the treatment of relapsing forms of multiple sclerosis...

Continue reading

ArcAroma AB: 201112 ArcAroma publicerar aktieägarbrev om oliveCEPT®

Pressmeddelande 2020-11-12ArcAroma (”ArcAroma” eller ”Bolaget”) återinför Aktieägarbrevet med målsättning att komplettera informationen i regulatoriska pressmeddelanden. Varje Aktieägarbrev planeras ha ett fokusområde inom en viss applikation som tema. Bifogat Aktieägarbrev nummer 9 handlar om oliveCEPT®.I ArcAromas senaste nyhetsbrev kan du bland annat läsa om följande:ArcAroma bedömer att marknaden för oliveCEPT® till Retrofit, dvs installation av oliveCEPT® i befintliga processlinjer, uppgår till totalt 14 miljarder kronor. Detta är en högre siffra än vad som tidigare meddelats.ArcAroma bedömer att det finns en betydande och lönsam eftermarknad, bestående av intäkter från serviceavtal och reservdelar. Över en tioårsperiod (bedömd ekonomisk livslängd för oliveCEPT®) beräknas eftermarknaden totalt uppgå till cirka 87 procent av det initiala...

Continue reading

Volvo Veteran Joins Terranet AB as CFO

Johan Wångblad Brings Vast Experience from Leading Swedish Carmaker to Terranet Team That’s Rapidly ExpandingLund, Sweden, November 12, 2020 – Terranet AB (Terranet/the Company), (Nasdaq: TERRNT-B.ST), developers of advanced driver-assist systems and the creators of breakthrough 3D motion awareness technology VoxelFlow, today announced the addition of Johan Wångblad as CFO, effective December 1, 2020.Mr. Wångblad joins Terranet after spending the last decades at Volvo Car Group, including the last twelve in Research and Development, where he held leading finance and accounting positions. In his most recent role at Volvo, Mr. Wångblad was Head of Operations at Volvo Car Technology Fund AB, the Volvo Group’s venture capital arm. Throughout his career, Mr. Wångblad helped set cost targets and prerequisites for manufacturing plants...

Continue reading

Terranet får ny CFO från Volvo Cars

Johan Wångblad tillträder som ny CFO på Terranet den 1 december. Johan har intill nyligen innehaft en tjänst som Head of Operations, Volvo Cars Tech Fund. Med sin långa och djupa bakgrund på Volvo och fordonsindustrin där han varit verksam i olika ledande roller inom både finans- och affärssidan, ser vi mycket framemot att jobba tillsammans med Johan för att utveckla bolaget vidare, både i fråga om plattformsutveckling samt på tjänstesidan för att expandera serviceaffären, konstaterar bolagets VD.Johan ersätter Mattias Larsson som går vidare till ny tjänst som CFO på AWA.För mer information kontakta:Pär-Olof Johannesson, VDparolof.johannesson@terranet.se+46 70 332 32 62Om TerraNet:TerraNet utvecklar mjukvara för radiobaserade lösningar och tredimensionell bildanalys för avancerat förarstöd och självkörande fordon (ADAS och AV). TerraNet...

Continue reading

Aspo Group CEO Aki Ojanen to retire in 2021

Aspo Plc Inside information  November 12, 2020 at 9:30 a.m.Aspo Group’s Chief Executive Officer Aki Ojanen has informed the Group’s Board of Directors that he will use the opportunity to retire in 2021 at the age of sixty. Aspo’s Board of Directors has started the application process for a new CEO, and in accordance with the jointly agreed schedule, Ojanen’s successor will start as the Group’s new CEO by the end of 2021.“I have been privileged to lead Aspo for twelve years. During this time, the company has grown and internationalized strongly. Acquisitions and investments have been made especially in the western markets, and in the eastern markets we have successfully focused on organic growth. The company has a good financial position and strong earnings potential. I feel this is a natural moment to leave my...

Continue reading

Aspo-konsernin toimitusjohtaja Aki Ojanen siirtyy eläkkeelle vuonna 2021

Aspo Oyj  Sisäpiiritieto    12.11.2020 klo 9.30Aspo Oyj:n toimitusjohtaja Aki Ojanen on ilmoittanut yhtiön hallitukselle käyttävänsä mahdollisuutta jäädä eläkkeelle vuonna 2021 täyttäessään kuusikymmentä vuotta. Aspon hallitus on käynnistänyt uuden toimitusjohtajan hakuprosessin, ja yhdessä sovitun aikataulun mukaisesti Ojasen seuraaja aloittaa konsernin toimitusjohtajana vuoden 2021 loppuun mennessä.  ”Olen ollut etuoikeutettu saadessani johtaa monialayhtiö Aspoa jo kahdentoista vuoden ajan. Tänä aikana yhtiö on kasvanut ja kansainvälistynyt voimakkaasti. Yrityskauppoja ja investointeja on tehty erityisesti länsimarkkinoilla, ja itämarkkinoilla olemme keskittyneet onnistuneesti orgaaniseen kasvuun. Yhtiön taloudellinen asema on hyvä ja tulospotentiaali vahva. Koen, että tämä on luonteva hetki jättää toimitusjohtajan tehtävät ja Aspo-konserni...

Continue reading

Blood Glucose Meter Market to Rise at 9.6% CAGR and Hit USD 15,415.6 Million by 2026; Driven by Rising Uptake of Non-Invasive Meters, says Fortune Business Insights™

Pune, India, Nov. 12, 2020 (GLOBE NEWSWIRE) — The global Blood Glucose Meter Market size is likely to expand considerably in the coming years due to advent of non-invasive devices. According to a report published by Fortune Business Insights, titled “Blood Glucose Meters: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 7,419.0 Mn in 2018. Fortune Business Insights states that this market is likely to reach US$ 15,415.6 Mn by 2026, thereby exhibiting a CAGR of 9.6%.Key Industry DevelopmentsIn June 2018, BioTel CareTM, introduced next-generation wireless blood glucose monitor for diabetes management. It is the first FDA-cleared, cellular-enabled glucometer which supports real-time transmission and consolidation of patient data in an FDA-cleared cloud.In June 2018, OK Biotech Co., Ltd., launched...

Continue reading

IVD Market is Forecast to Rise at 4.5% CAGR and Reach USD 87.11 Billion by 2026; Adoption of New Techniques for Rapid Disease Diagnosis Will Encourage Growth, says Fortune Business Insights™

Pune, India, Nov. 12, 2020 (GLOBE NEWSWIRE) — According to the report, the global IVD Market size was valued at USD 61.22 Billion in 2018 is predicted to reach USD 87.11 Billion by 2026, exhibiting a CAGR of 4.5% during the forecast period. North America generated a revenue of USD 23.09 Billion in 2018 and is anticipated to emerge as a dominant region in the global IVD Market during the forecast period. Adequate and favorable government regulations, well-established diagnostic infrastructure, adoption of technologically advanced diagnostic techniques, and presence of prominent key market players in this region are some of the significant factors anticipated the drive the growth of the market in North America. INDUSTRY DEVELOPMENT:July 2018: Thermo Fisher Scientific launched Phadia 200 for diagnosis of allergy & autoimmune conditions....

Continue reading

Regarding the number of votes granted by the shares of INVL Baltic Real Estate from 11 November 2020

On 9 November 2020 upon the end of the share buy-back process of INVL Baltic Real Estate (hereinafter – “the Company”), the Company acquired the 100,431 Company‘s shares for EUR 186,058.48 which constitutes 0.8 percent of the authorized capital of the Company. The shareholders were paid for on 11 November 2020.According to the Law on Securities of the Republic of Lithuania, the shares owned by the Company are not considered to be deducted from the total number of shares granted with voting right of the issuer and are not counted into the quorum of the General Shareholders Meeting of the Company.Announcement of shares issued by Company:The person authorized to provide additional information:Real Estate Fund Manager of Management CompanyVytautas BakšinskasE-mail vytautas.baksinskas@invl.com 

Continue reading

Dėl „INVL Baltic Real Estate“ akcijų suteikiamų balsų skaičiaus nuo 2020 m. lapkričio 11 d.

2020 m. lapkričio 9 d. pasibaigus „INVL Baltic Real Estate“ (toliau – „Bendrovė“) akcijų išpirkimo procesui, Bendrovė įgijo iš 6 akcininkų 100 431 savų akcijų už 186 058,48 eurų, kas sudaro 0,8 proc. Bendrovės įstatinio kapitalo. Su šiais akcininkais buvo atsiskaityta 2020 m. lapkričio 11 d.Vadovaujantis Lietuvos Respublikos vertybinių popierių įstatymu, laikoma, kad Bendrovės turimos savos akcijos nėra išskaičiuojamos iš bendro Bendrovės akcijų suteikiamų balsų skaičiaus ir yra neįskaitomos skaičiuojant Bendrovės visuotinio akcininkų susirinkimo kvorumą.Skelbiame Bendrovės išleistų akcijų informaciją:Asmuo, įgaliotas suteikti papildomą informaciją:Valdymo įmonės Nekilnojamojo turto fondo valdytojasVytautas BakšinskasEl.paštas vytautas.baksinskas@invl.com

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.